Brief: Aerovate Therapeutics Announces Initiation Of Impahct Phase 2B/Phase 3 Trial Of Av-101 In Pulmonary Arterial Hypertension
15/12/2021 13:30
Dec 15 (Reuters) - Aerovate Therapeutics Inc AVTE.O :
* AEROVATE THERAPEUTICS ANNOUNCES INITIATION OF IMPAHCT
PHASE
2B/PHASE 3 TRIAL OF AV-101 IN PULMONARY ARTERIAL HYPERTENSION
* AEROVATE THERAPEUTICS INC - EXPECTS TO REPORT TOP-LINE
RESULTS
FROM PHASE 2B PORTION OF IMPAHCT IN MID-2023
Source text for Eikon: ID:nGNX9vRqqG
Further company coverage: AVTE.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Jade Biosciences
See all newsBrief: Jade Biosciences Announces Preclinical Data Characterizing Jade301, A Potentially Best-In-Class, Half-Life-Extended Anti-Ifn-Β Monoclonal Antibody In Development For Dermatomyositis, At Eadv 2026
U.S. RESEARCH ROUNDUP-Cardinal Health, Lumentum Holdings, Public Storage
Jade Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
Jade Biosciences Q2 net loss widens as costs rise
Brief: Jade Biosciences, Inc Q2 Cash & Investments USD 461.2 Million